查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922951

女性用事后紧急避孕药市场依活性成分、剂型、给药途径、销售管道及最终用户划分－2026年至2032年全球预测

Female Emergency Contraceptive Pill Market by Active Ingredient, Dosage Form, Dose Regimen, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，女性用事后紧急避孕药市场价值将达到 6.5321 亿美元，到 2026 年将成长至 7.0046 亿美元，到 2032 年将达到 11.8344 亿美元，复合年增长率为 8.86%。

主要市场统计数据
基准年 2025 6.5321亿美元
预计年份：2026年 7.046亿美元
预测年份：2032年 11.8344亿美元
复合年增长率 (%) 8.86%

这是一部权威的导论，全面回顾了影响现代医疗保健中女性用事后紧急避孕药的临床、监管、分销和人口统计因素。

女性用事后紧急避孕药领域正处于战略十字路口，临床创新、监管细则和不断变化的获取模式在此交会。本导言旨在帮助读者理解产品层面的差异、分销系统和消费者群体特征如何共同影响商业性和公共卫生结果。透过围绕活性成分、获取管道、人口需求驱动因素、剂型和不断变化的政策展开讨论，以下分析为制定有针对性的战略应对措施奠定了基础。

监管现代化、数位医疗整合和供应链创新将如何共同重塑事后紧急避孕药的取得管道和商业策略

在政策现代化、数位医疗融合以及消费者期望不断变化等因素的推动下，事后紧急避孕药的研发、取得和配方方式发生了变革性转变。首先，监管政策的调整扩大了许多地区的网路基地台，迫使药局和远端医疗服务提供者重新设计服务模式，以实现当日取药和线上购买。其次，产品配方和临床证据的进步改变了临床医生和消费者评估各种方案的方式，更加重视易用性、药效持续时间和副作用情况。第三，供应链创新和无需低温运输的配送方式减少了物流摩擦，加快了关键网路基地台的补货速度，并提高了库存可靠性。

评估2025年美国关税措施及其对整个价值链的采购、供应多元化、库存管理和定价实践的影响

2025年实施的关税和贸易政策调整，为依赖国际采购的活性药物成分和製剂产品的供应链管理、采购和定价动态带来了新的复杂性。关税调整加剧了依赖跨境采购的製造商和经销商的成本敏感性，促使他们即时采取多项营运措施以保障利润，包括供应商多元化、关键原材料近岸采购以及重新谈判长期合约。同时，采购团队加快了多家供应商和采购管道的资格审核，以降低海关延误和合规成本上升带来的前置作业时间风险。

深入分析策略重点与原料药属性、给药途径、目标族群、销售管道和剂型偏好之间的关联。

详细的細項分析揭示了活性成分、销售管道、终端用户群体、销售管道和剂型等方面的独特商业和临床特征，这些特征共同决定了产品的定位和部署优先顺序。以活性成分分類的市场研究包括levonorgestrel（评估剂量分别为 0.75 毫克和 1.5 毫克）、米非司酮（10 毫克）和醋酸乌利司他（30 毫克）。每种活性成分的疗效、适应症和监管过程均不相同，这会影响标籤、咨询要求和竞争分析。依销售管道划分，非处方药与处方笺的取得限制直接影响消费者的购买管道、药剂师的职责和销售点教育需求，进而影响製造商的互动策略。

美洲、欧洲、中东和非洲以及亚太地区的区域监管差异、分销能力和文化期望如何影响差异化的市场准入和商业化方法？

区域趋势对法规结构、分销基础设施和消费者预期产生了深远影响，导緻美洲、欧洲、中东和非洲地区以及亚太地区的市场行为存在差异。在美洲，监管现代化和远端医疗的普及增加了网路基地台，同时也鼓励药局主导相关倡议，以确保及时供应。支付方结构和公共卫生宣传活动也在影响介入措施融入更广泛的生殖健康服务的程度。欧洲、中东和非洲地区的情况则更为多样化，一些地区强调严格的临床通讯协定和配药控制，而其他地区则转向更自由的取得模式。因此，监管机构的应对措施以及与当地相关人员的沟通是成功实施的关键。

竞争格局分析揭示了现有经销商、灵活的学名药和数位化优先的分销商如何融合，从而重新定义药品获取、可靠性和通路创新。

女性事后紧急避孕药市场的竞争格局由老牌製药公司、专业生殖健康产品製造商和数位化原生经销商组成，它们都在重新定义产品的覆盖范围和便利性。老牌製药公司继续利用其深厚的监管专业知识、广泛的生产基地以及与机构负责人建立的长期合作关係，以维持其产品在商店的占有率和临床医生的信任。同时，利基市场和非专利製造商专注于成本效益高的配方和灵活的营运模式，使其能够快速应对因采购趋势和关税变化而导致的供应中断。数位化优先的新兴参与企业和线上药局透过便利、快速和私密的配送模式，加速了消费者对紧急避孕药的接受度，从而改变了传统零售的动态。

这是一份实用的策略指南，旨在帮助领导者整合监管合规、供应商多元化、高阶需求预测和通路特定商业化，从而增强企业韧性并实现成长。

产业领导者应采取多管齐下的策略，平衡监管合规、供应链韧性和以消费者为中心的配送，以掌握机会并管控风险。首先，应积极主动地与监管机构和支付方沟通，预测政策变化，并在有证据支持的情况下，简化非处方药过渡和扩大用药管道。其次，应实现供应商网路多元化，并对区域契约製造进行认证，以最大限度地减少关税相关干扰，并缩短前置作业时间。同时，应部署先进的需求预测工具，在不影响服务水准的前提下优化库存。

一项综合性的混合方法研究设计，结合了关键相关人员访谈、监管资讯综合、供应链图谱绘製和情境分析，以得出检验的策略见解。

本研究采用混合方法，将一手质性研究与二手证据综合相结合，以确保研究结果的可靠检验。一手研究包括对关键行业专家、药剂师、监管专家和分销经理进行结构化访谈，以收集有关药品获取、配製行为和运营挑战的实证见解。这些定性见解与二手监管文件、临床文献和公共公告相结合，以阐明观察到的模式并检验新出现的主题。

整合监管情报、供应链韧性和管道特定参与以维持事后紧急避孕药的可及性和公共卫生结果的概要

总之，女性用事后紧急避孕药格局正受到不断变化的监管法规、供应链重组以及消费者获取偏好转变等因素的共同影响而重塑。能够预见政策趋势、建立稳健的筹资策略并针对合适的销售管道进行行销活动的相关人员将获得决定性优势。透过活性成分或剂型进行产品差异化，并结合针对特定年龄层的精准推广和合理的销售管道组合，可以更有效地将临床疗效与使用者需求相匹配。此外，区域差异也需要製定符合法规环境和文化期望的在地化策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 销售管道分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章女性用事后紧急避孕药市场（依活性成分划分）

  • levonorgestrel
  • 醋酸乌利司他
  • 米非司酮

第九章女性用事后紧急避孕药市场（以剂型划分）

  • 凝胶
  • 药片

第十章女性用事后紧急避孕药市场（依给药途径划分）

  • 单一剂量
    • 标准管理期间
    • 延长行政期间
  • 分次服用
    • 12小时间隔
    • 24小时间隔

第十一章女性用事后紧急避孕药市场销售管道

  • 医院药房
  • 网路药房
  • 零售药房

第十二章女性用事后紧急避孕药市场（依最终用户划分）

  • 青少年
    • 15-17岁
    • 18-19岁
  • 年轻人
    • 20-24岁
    • 25-29岁
  • 成人
    • 30-34岁
    • 35岁或以上

第十三章女性用事后紧急避孕药市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章女性用事后紧急避孕药市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国女性用事后紧急避孕药市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国女性用事后紧急避孕药市场

第十七章：中国女性用事后紧急避孕药市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Afaxys Pharma LLC
  • Apotex Inc.
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Foundation Consumer Healthcare LLC
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals Limited
  • HLL Lifecare Limited
  • Laboratoire HRA Pharma SAS
  • Lupin Limited
  • Mankind Pharma Limited
  • Organon & Co.
  • Perrigo Company plc
  • Pfizer Inc.
  • Piramal Enterprises Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-867BED9A9E7A

The Female Emergency Contraceptive Pill Market was valued at USD 653.21 million in 2025 and is projected to grow to USD 700.46 million in 2026, with a CAGR of 8.86%, reaching USD 1,183.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 653.21 million
Estimated Year [2026] USD 700.46 million
Forecast Year [2032] USD 1,183.44 million
CAGR (%) 8.86%

An authoritative introduction framing clinical, regulatory, distributional, and demographic forces shaping the female emergency contraceptive landscape in contemporary healthcare

The female emergency contraceptive landscape sits at a strategic crossroads where clinical innovation, regulatory nuance, and shifting access paradigms converge. This introduction positions the reader to appreciate how product-level differences, distribution frameworks, and consumer demographics collectively shape commercial and public-health outcomes. By framing the discussion around active ingredients, channels of access, demographic demand drivers, dosage formats, and evolving policy, the following analysis establishes context for targeted strategic response.

Across therapeutic modalities, differences in mechanism of action, dosing regimens, and regulatory classifications have meaningful implications for prescribing practices, over-the-counter availability, and consumer choice. As regulatory agencies reconcile competing evidence streams and jurisdictions adapt their pharmacy and telehealth rules, stakeholders must anticipate both near-term operational impacts and longer-term shifts in demand elasticity. This introduction prepares commercial and clinical leaders to interpret subsequent sections, which delve into transformative market shifts, the 2025 U.S. tariff environment, granular segmentation insights, and regionally differentiated considerations that collectively inform robust go-to-market strategies.

How regulatory modernization, digital health integration, and supply-chain innovation collectively recalibrate access pathways and commercial strategies for emergency contraceptives

Transformative shifts are reshaping how female emergency contraceptives are developed, accessed, and prescribed, driven by policy modernization, digital health integration, and evolving consumer expectations. First, regulatory adaptations have expanded points of access in many settings, prompting pharmacies and telehealth providers to redesign service models to accommodate same-day access and online fulfillment. Second, advances in product formulations and comparative clinical evidence have altered how clinicians and consumers evaluate options, emphasizing ease of use, efficacy windows, and side effect profiles. Third, supply chain innovations and cold-chain-independent distribution have reduced logistical friction, enabling faster replenishment and more reliable stock at critical access points.

Consequently, commercial strategies have shifted from broad-based promotional tactics toward more targeted, education-centric outreach that addresses both healthcare professional decision-making and consumer awareness. These shifts are amplified by digital engagement channels that allow for precise segmentation and rapid feedback loops, enabling iterative refinement of messaging and service design. Taken together, the landscape now rewards organizations that integrate regulatory foresight, product differentiation, and customer-centric channel orchestration to capture sustainable value.

Assessment of the 2025 U.S. tariff interventions and how they reshaped procurement, supplier diversification, inventory posture, and pricing approaches across the value chain

The imposition of tariffs and trade-policy shifts in 2025 introduced a new layer of complexity to supply-chain management, procurement, and pricing dynamics for products that rely on internationally sourced active pharmaceutical ingredients and finished doses. Tariff adjustments increased the cost sensitivity of manufacturers and distributors who rely on cross-border procurement, prompting several immediate operational responses including supplier diversification, nearshoring of critical inputs, and renegotiation of long-term contracts to protect margin integrity. In parallel, procurement teams accelerated efforts to qualify multiple suppliers and routings to mitigate lead-time risk arising from customs delays and elevated compliance costs.

Beyond direct cost impacts, the tariff environment has influenced strategic decisions about inventory posture and channel pricing. Organizations reassessed safety-stock policies and invested in predictive demand analytics to balance service levels with capital efficiency. Some manufacturers prioritized contractual commitments with national distributors to secure shelf presence despite incremental landed costs, while others pursued cooperative purchasing or consortia arrangements to share tariff-related burdens. Importantly, the tariff-driven recalibration varied by product attributes: formulations with narrow supplier bases or specialized manufacturing steps faced steeper operational strain than widely produced tablet formulations. Ultimately, the 2025 tariff landscape reinforced the importance of supply-chain resilience as a core competency, compelling firms to align procurement, regulatory, and commercial planning more tightly than before.

In-depth segmentation-driven analysis linking active ingredient nuances, access modalities, demographic cohorts, sales channels, and dosage form preferences to strategic priorities

A nuanced segmentation lens reveals diverse commercial and clinical dynamics across active ingredient, distribution channel, end-user age group, sales channel, and dosage form that together determine product positioning and outreach priorities. Based on Active Ingredient, market studies differentiate Levonorgestrel, which is assessed at both 0.75 mg and 1.5 mg dosages; Mifepristone, represented at 10 mg; and Ulipristal Acetate, evaluated at 30 mg. Each active ingredient carries distinct efficacy profiles, windows of use, and regulatory histories that influence labeling, counseling requirements, and competitive narrative. Based on Distribution Channel, distinctions between Over The Counter availability and Prescription-only access directly affect consumer pathways, pharmacist obligations, and point-of-sale educational needs, thus shaping manufacturer engagement strategies.

Based on End User Age Group, analysis spans age cohorts 15-19, 20-24, 25-29, 30-34, and 35+, illuminating how life stage, reproductive intentions, and health-service utilization patterns drive heterogeneous demand. Younger cohorts often demonstrate higher sensitivity to privacy and convenience, elevating the importance of discreet channels and digital touchpoints, whereas older cohorts may engage more directly with clinical providers. Based on Sales Channel, the differentiation among Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy underscores the operational and regulatory nuances of institutional procurement, e-commerce fulfillment, and point-of-sale counseling. Finally, based on Dosage Form, the presence of Gel and Tablet formats highlights formulation preferences, adherence considerations, and manufacturing complexity. Together, these segmentation lenses inform targeted clinical communication, channel-tailored promotions, and supply-chain planning to optimize access across population segments.

How regional regulatory diversity, distribution capabilities, and cultural expectations across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated access and commercialization approaches

Regional dynamics exert a powerful influence on regulatory frameworks, distribution infrastructure, and consumer expectations, leading to differentiated market behaviors across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory modernization and telehealth expansion have increased points of access while stimulating pharmacy-led initiatives to support timely availability; payer structures and public-health campaigns also influence the degree to which interventions are integrated into broader reproductive-health services. Moving to Europe, Middle East & Africa, heterogeneity is pronounced: some jurisdictions emphasize tight clinical protocols and prescription controls, while others have moved toward more liberalized access models; consequently, regulatory navigation and localized stakeholder engagement remain essential for successful rollout.

The Asia-Pacific region presents a mix of urbanized markets with advanced e-commerce ecosystems and jurisdictions where supply-chain constraints and varying regulatory timelines necessitate bespoke commercialization approaches. Across all regions, differences in cultural norms, health-system financing, and pharmacy practice drive distinct expectations for counseling, packaging, and labeling. Therefore, global strategic planning must accommodate regional regulatory frameworks, channel readiness, and demographic demand vectors in order to effectively prioritize investments and localization efforts.

Competitive landscape analysis revealing how legacy manufacturers, agile generic producers, and digital-first distributors converge to redefine access, credibility, and channel innovation

Competitive dynamics in the female emergency contraceptive space reflect a mix of legacy pharmaceutical players, specialized reproductive-health manufacturers, and digitally native distributors that are redefining reach and convenience. Established pharmaceutical companies continue to leverage deep regulatory expertise, broad manufacturing footprints, and long-standing relationships with institutional buyers to maintain shelf presence and clinician trust. At the same time, niche manufacturers and generic producers focus on cost-efficient formulations and agility, enabling faster responses to procurement shifts and tariff-induced supply interruptions. Digital-first entrants and online pharmacies are accelerating consumer adoption through convenience, rapid delivery, and discreet fulfillment models, altering conventional retail dynamics.

These competing forces create opportunities for strategic partnerships, co-marketing arrangements, and distribution agreements that bridge institutional credibility with digital reach. Moreover, intellectual-property considerations, manufacturing specialization for specific dosage forms, and regulatory dossiers for varying active ingredients differentiate competitive positioning. Firms that combine clinical credibility, manufacturing resilience, and channel innovation will be best positioned to capture long-term demand while navigating pricing pressures and regulatory scrutiny.

Actionable strategic playbook for leaders to synchronize regulatory engagement, supplier diversification, advanced forecasting, and channel-specific commercialization to build resilience and growth

Industry leaders should adopt a multi-pronged strategy that balances regulatory engagement, supply-chain resilience, and consumer-centric distribution to capture opportunity while managing risk. First, invest in proactive regulatory and payer engagement to anticipate policy shifts and to streamline pathways for over-the-counter transitions or expanded access where evidence supports them. Second, diversify supplier networks and qualify regional contract manufacturers to minimize exposure to tariff-related disruption and to shorten lead times, while implementing advanced demand-forecasting tools to optimize inventory without compromising service levels.

Third, prioritize channel-tailored commercialization: enhance pharmacist-facing education and point-of-sale counseling for over-the-counter channels, while building seamless telehealth and e-commerce integrations to meet privacy-sensitive cohorts. Fourth, refine product portfolios by aligning active ingredient positioning and dosage-form offerings with distinct end-user cohorts to maximize clinical appropriateness and market relevance. Finally, pursue strategic partnerships that combine distribution scale with digital capabilities to expand reach and improve the end-user experience. Taken together, these actions will strengthen market responsiveness, preserve margin integrity, and support sustained access.

Comprehensive mixed-methods research design integrating primary stakeholder interviews, regulatory synthesis, supply-chain mapping, and scenario analysis to produce validated strategic insights

This research employs a mixed-methods approach that integrates primary qualitative inquiry with secondary evidence synthesis to ensure robust, triangulated insights. Primary research included structured interviews with key opinion leaders, pharmacists, regulatory specialists, and distribution managers to capture experiential knowledge about access, prescribing behavior, and operational challenges. These qualitative inputs were synthesized with secondary regulatory documentation, clinical literature, and public policy announcements to contextualize observed patterns and to validate emergent themes.

Analytical methods combined thematic analysis of interview transcripts with cross-sectional assessment of distribution channel behaviors and supplier network configurations. Where relevant, scenario planning workshops informed sensitivity testing of tariff and regulatory contingencies, while supply-chain mapping exercises identified critical nodes and single-source risk factors. Throughout, the methodology emphasized corroboration across data sources and transparency in assumptions to support actionable insights for stakeholders seeking to align clinical considerations, commercial objectives, and operational execution.

Concluding synthesis on aligning regulatory intelligence, supply-chain resilience, and channel-tailored engagement to sustain access and public-health outcomes in emergency contraception

In conclusion, the female emergency contraceptive landscape is being reshaped by a confluence of regulatory evolution, supply-chain recalibration, and shifting consumer access preferences. Stakeholders that anticipate policy movement, build resilient procurement strategies, and tailor channel-appropriate engagement will gain a decisive advantage. Product differentiation across active ingredients and dosage forms, when combined with targeted outreach to distinct age cohorts and the right sales-channel mix, enables more effective matching of clinical benefit to user needs. Additionally, regional variations necessitate localized strategies that respect regulatory context and cultural expectations.

As a result, decision-makers should prioritize investments that strengthen regulatory intelligence, supplier flexibility, and digital distribution capabilities. By doing so, organizations can both safeguard continuity of supply in the face of trade and tariff pressures and create more responsive pathways to reach consumers who require timely access to emergency contraception. The strategic imperative is clear: align clinical evidence, channel design, and operational resilience to sustain access and to support public-health objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Female Emergency Contraceptive Pill Market, by Active Ingredient

  • 8.1. Levonorgestrel
  • 8.2. Ulipristal Acetate
  • 8.3. Mifepristone

9. Female Emergency Contraceptive Pill Market, by Dosage Form

  • 9.1. Gel
  • 9.2. Tablet

10. Female Emergency Contraceptive Pill Market, by Dose Regimen

  • 10.1. Single Dose
    • 10.1.1. Standard Window
    • 10.1.2. Extended Window
  • 10.2. Split Dose
    • 10.2.1. 12 Hour Interval
    • 10.2.2. 24 Hour Interval

11. Female Emergency Contraceptive Pill Market, by Sales Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Female Emergency Contraceptive Pill Market, by End User

  • 12.1. Adolescents
    • 12.1.1. 15 To 17 Years
    • 12.1.2. 18 To 19 Years
  • 12.2. Young Adults
    • 12.2.1. 20 To 24 Years
    • 12.2.2. 25 To 29 Years
  • 12.3. Adults
    • 12.3.1. 30 To 34 Years
    • 12.3.2. 35 Years And Above

13. Female Emergency Contraceptive Pill Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Female Emergency Contraceptive Pill Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Female Emergency Contraceptive Pill Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Female Emergency Contraceptive Pill Market

17. China Female Emergency Contraceptive Pill Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Afaxys Pharma LLC
  • 18.6. Apotex Inc.
  • 18.7. Bayer AG
  • 18.8. Cipla Limited
  • 18.9. Dr. Reddy's Laboratories Ltd.
  • 18.10. Foundation Consumer Healthcare LLC
  • 18.11. Gedeon Richter Plc.
  • 18.12. Glenmark Pharmaceuticals Limited
  • 18.13. HLL Lifecare Limited
  • 18.14. Laboratoire HRA Pharma SAS
  • 18.15. Lupin Limited
  • 18.16. Mankind Pharma Limited
  • 18.17. Organon & Co.
  • 18.18. Perrigo Company plc
  • 18.19. Pfizer Inc.
  • 18.20. Piramal Enterprises Limited
  • 18.21. Sandoz International GmbH
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STANDARD WINDOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STANDARD WINDOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STANDARD WINDOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY EXTENDED WINDOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY EXTENDED WINDOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY EXTENDED WINDOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 12 HOUR INTERVAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 12 HOUR INTERVAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 12 HOUR INTERVAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 24 HOUR INTERVAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 24 HOUR INTERVAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 24 HOUR INTERVAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15 TO 17 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15 TO 17 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15 TO 17 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 18 TO 19 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 18 TO 19 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 18 TO 19 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20 TO 24 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20 TO 24 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20 TO 24 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25 TO 29 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25 TO 29 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25 TO 29 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 TO 34 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 TO 34 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 TO 34 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 184. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 185. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 186. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 217. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 219. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 228. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 229. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 230. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)